|本期目录/Table of Contents|

[1]刘伟,梁晓春.中医药治疗宫颈癌研究进展[J].环球中医药,2013,6(07):554-0.
 LIU Wei,LIANG Xiao chun..Research progress in traditional Chinese medicine treatment of cervical carcinoma[J].,2013,6(07):554-0.
点击复制

中医药治疗宫颈癌研究进展()
     
分享到:

《环球中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
第6卷
期数:
2013年07期
页码:
554-0
栏目:
综述
出版日期:
2013-07-06

文章信息/Info

Title:
Research progress in traditional Chinese medicine treatment of cervical carcinoma
作者:
刘伟;梁晓春
Author(s):
LIU Wei LIANG Xiaochun.
Department of Traditional Chinese Medicine,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China
关键词:
宫颈癌中医中药综述
Keywords:
Cervical cancerTCMReview
分类号:
R73733
DOI:
-
文献标志码:
A
摘要:
近年来宫颈癌发病率有着逐渐年轻化的趋势,西医针对宫颈癌主要采用手术及术后放化疗的治疗方式,但随之而来的是一系列的术后并发症以及放化疗所带来的不良反应。祖国医学对于宫颈癌的发生发展有着较为独特的认识,认为宫颈癌发病原因主要在于房劳多产、饮食不节,情志不舒等所致的湿热、痰浊、瘀毒等邪气外袭胞宫,郁而不解,损伤冲任带脉,根本原因则是正虚邪实。近年来众多研究表明,中药对于促进宫颈癌细胞凋亡,减少化放疗的副作用有较好的效果。但相关基础研究仍较薄弱,许多中药的有效成分及发挥作用的机制不甚明了,复方的研究缺乏多中心、大样本的长期随访研究。
Abstract:
The incidence rate of cervical cancer has got a gradually younger trend in recent years. Operation and postoperative chemotherapy and radiotherapy are currently the main treatment for cervical cancer . The Chinese medicine has a special knowledge of the occurrence and development of cervical cancer,which mainly lies in the damp heat, phlegm and blood stasis attacking the uterus caused by unrestrained sex, improper diet, sluggish emotion and so on. They are depressed and confused, which injure the Chong、 Ren and Dai channel.But the essential reason is the asthenia healthy qi and sthenia pathogenic factor syndrome . In recent years, many studies showed that the traditional Chinese medicine(TCM) has got a good effect of promoting the apoptosis of cervical cancer cells and can also reduce the side effects of chemotherapy and radiotherapy . But the related basic research is still weak and the effective ingredients and mechanism of TCM are still not clear enough.Moreover, compound studies lack a multicenter, large sample of longterm followup studies.

参考文献/References:

[1]顾晓梅,张玉泉.宫颈癌的流行病学高危因素研究进展[J].中国妇幼保健,2007,22(35):50735075.
[2]Beaudenon S,Huibregtse JM.HPV E6,E6AP and cervical cancer[J].BMC Biochem,2008,21(9sl):S4.
[3]Oliveira A,Delqado C,Verdasca N,et al.Biomarkers of cervical carcinogenesis associated with genital human papillomavirus infection[J].Acta Med Port,2013,26(2):139144.
[4]Kovács K, Varnai AD, Bollmann M,et al. Prevalence and genotype distribution of multiple human papillomavirus infection in the uterine cervix: a 75year longitudinal study in a routine cytologybased screening population in West Germany[J]. J Med Virol,2008, 80(10): 18141823.
[5]Munagala R, Donà MG, Rai SN, et al. Significance of multiple HPV infection in cervical cancer patients and its impact on treatment response[J]. Int J Oncol, 2009, 34(1): 263271.
[6] Arbyn M,Sasieni P,Meijer CJ,et al.Clinical applications of HPV testing:a summary of metaanalyses[J].Vaccine,2006,24(3):7889.
[7] Bulk S,Berkhof J,Bulkmana NW,et al. Preferential risk of HPV l6for squamous cell carcinoma and of HPV 18 for adenocarcinoma 0f the cervix compared to women with normal cytology in the Netherlans[J].Br J Cancer,2006,94(1):171175.
[8]Brychtat E, Sedlakova E,Kolar Z,et al. Protooncogene Cmyc in uterine cervix carcinoma genesis [J].Neoplasma,2004,51(2):8490.
[9]Lu W,Pochampally R,Chen L,et al. Nucle exclusion of p53 in a subset of tumors requires mdm2 function[J]. Oncogene,2000(18):232.
[10]Sampedro CF,Cano SG,Sampedro SF,et al. Telomerase and telomere dynamics in ageing and cancer current status and future directions[J].Clin Transl Oncol,2007,9(3):145154.
[11]Renaud S,Loukinov D,Abdullaer Z,er al.Dual role of DNA methylation inside and outside of CTCFbinding regions in the transciptional regulation of the telomerase hTERT gene[J].Nuc Acids Res,2007,35(4):12451256.
[12]罗琼,熊树华,徐国荣,等.端粒酶在宫颈癌及其癌前病变组织中的表达及意义[J].实用癌症杂志,2009,24(3):242244.
[13]Kitchener HC,Castle PE,Cox JT.Achievements and limitations of cervical cytology screening[J].Vaccine,2006,24(3):6370.
[14]吕国聪.阴道镜下病理活检对宫颈病变和早期宫颈癌筛查诊断的重要价值[J].中外医学研究,2011,9(29):147.
[15]李晶晶,龙颖,姚德生.宫颈癌治疗对全身各系统的影响[J].医学综述,2012,18(15):24152417
[16]Vistad I,Fossa SD,Kristensen GB,et al.Chronic fatigue and its correlates in longterm survivors of cervical cancer treated with radiotherapy[J].BJOG,2007,114(9):11501158.
[17]郑怡真,吴冬梅,刘倩,等.宫颈上皮内瘤变及宫颈癌中医证型演变规律研究[J].中国医药,2011,12(6):15431545.
[18]刘倩,吴冬梅,郑怡真,等.宫颈上皮内瘤变及宫颈癌中医证候与MCM5及p16INK4a相关性研究[J].福建中医药大学学报,2012,22(4):1315.
[19]崔林.庞泮池教授治疗宫颈癌的临床经验[J].湖南中医药导报,2003,9(11):6.
[20]高超,刘颖,蔡晓敏,等.白花蛇舌草对U14 宫颈癌抗肿瘤作用的实验研究[J].实用癌症杂志, 2007,11:557.
[21]陈小军,顾立刚,李佩文,等.榄香烯乳对人宫颈癌Hela细胞转录因子ELK1及其靶基因的影响[J].中国中医药信息杂志,2008,15(1):2627.
[22]王恩军,靳玮,王哲,等.山茱萸多糖诱导宫颈癌细胞凋亡及Bax蛋白表达的变化[J].中国实验方剂学杂志,2012,18(10):260262.
[23]罗惠娟,徐建平,黎清,等.4种中药多糖及胸腺肽对U14宫颈癌荷瘤鼠脾脏和瘤内免疫影响的比较[J].中国病理生理杂志,2012,28(10):18951900.
[24]李丹,张蔚,李福敏,等.苦参碱对宫颈癌Hela细胞的作用[J].武汉大学学报(医学版),2008,29(1):2830.
[25]高艳娥,郭金珠,惠慧,等.莪术醇对人宫颈癌CASKI细胞增殖抑制及促凋亡作用的研究[J].现代肿瘤医学,2009,17(10):18361839.
[26]狄晓鸿,高英敏,郭红云.黄连素对人宫颈癌Hela细胞株的体外作用研究[J].中国中医药信息杂志,2008,15(1):3032.
[27]王灵丽.白花败酱总皂苷抗小鼠宫颈癌的活性探讨[J].国际中医中药杂志,2011,33(12):10831085.
[28]王玉荣,王泽时.加味四君子汤抗小鼠宫颈癌作用的研究[J].陕西中医学院学报,2003,4(4):11.
[29]陈海丽,韩凤娟,宫艳秋,等.中药复方儿黄散对宫颈癌Hela细胞增殖抑制及Bcl2蛋白表达的影响[J].现代肿瘤医学,2010,18(11):21022104.
[30]楼娇英,金哲.消毒栓血清药对宫颈癌SiHa细胞凋亡及周期的影响[J].北京中医药,2008,27(7):563565.
[31]孙红,刘伟伟,姜红伟.八珍汤对宫颈癌术后化疗患者血清肿瘤坏死因子及免疫球蛋白水平的影响[J].国际中医中药杂志,2011,33(8):722723.
[32]徐如意,李丹,李力等.鱼腥草联合中药汤剂治疗宫颈上皮内瘤变、HPV感染并宫颈炎的临床观察[J].甘肃中医,2010,23(6):3840.
[33]赵瑞华.李光荣教授治疗宫颈癌的经验[C]∥全国第五次中医妇科学术研讨会论文汇编.2005:158160.
[34]徐侠,张培影.中药清热方干预治疗宫颈高危型HPV感染的对比研究[J].中国中医药远程教育,2008,6(10):11671169.
[35]张培影,刘凌,王旭波,等.熏洗一号配合放疗治疗Ⅰa~Ⅱb期子宫颈癌合并HRHPV感染的临床研究[J].中国中西医结合杂志,2011,31(8):10661069.
[36]丁小凡,李德杏,赵林.清热补益中药对放射诱导肠损伤的临床防治和实验研究[J].中华放射医学与防护杂志,2004,24(1):4951.
[37]Yu Zhichong,Yuan Hongxiang.Effects of Moxibustion on Hemoglobin and Immunoglobulin in Cervical Cancer Patients Undergoing Radiotherapy[J].Journal of Acupuncture and Tuina Science,2011,09(6):359361.
[38]吴宁.蛭癌宁治疗宫颈癌的疗效观察[J],上海中医药杂志,2006,40(4):4546.
[39]董晶,赵西侠,舒瑾.中药保留灌肠预防宫颈癌放射性直肠炎的临床观察[J],现代肿瘤医学,2012,20(7):14211423.
[40]李道成,许丽绵,邓高丕.平胃散促进宫颈癌根治术后胃肠功能恢复的临床研究[J],新中医,2008,40(3):2021.
[41]徐兰凤,喻志冲,詹臻,等.艾灸对宫颈癌放疗患者免疫调节因子的影响[J].中国针灸,2003,23(1):4143.
[42]袁红香,喻志冲,成慧珍,等.艾灸对宫颈癌放疗患者血红蛋白的影响[J].上海针灸杂志,2003,22(7):3334.
[43]于玲,徐兰凤.艾灸对宫颈癌放疗患者免疫功能的影响[J].针灸临床杂志,2004,20(3):4749.

相似文献/References:

[1]秦兰.宫颈癌术后同步放化疗辅以中药内服的临床观察及毒副反应分析[J].环球中医药,2013,6(06):424.
 QIN Lan..Clinical effect and toxicity reaction of radiotherapy and chemotherapy combined with Chinese medicine in treating cervical cancer[J].,2013,6(07):424.
[2]张翔 梁晓春.补肾活血法治疗糖尿病周围神经病变的研究进展[J].环球中医药,2014,7(06):492.
 ZHANG Xiang,LIANG Xiao chun..Research progress in Bushen Huoxue treatment of diabetic peripheral neuropathies[J].,2014,7(07):492.

备注/Memo

备注/Memo:

作者单位:100730北京,中国医学科学院 北京协和医学院 北京协和医院中医科
作者简介:刘伟(1986- ),女,2012级在读博士研究生。研究方向:中西医结合防治糖尿病慢性并发症 Email:gudongkui@126.com
通讯作者:梁晓春(1956- ),女,主任医师,博士生导师。中国中西医结合学会常务理事,中国中西医结合学会内分泌代谢病专业委员会副主任委员,北京中西医结合学会糖尿病专业委员会主任委员。研究方向:中西医结合防治糖尿病慢性并发症。Email:xcliang@vip.sina.com
更新日期/Last Update: 1900-01-01